PGEN
Closed
Precigen Inc
1.45
+0.03 (+2.11%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.42
Day's Range: 1.395 - 1.5
Send
sign up or login to leave a comment!
When Written:
1.01
Precigen Inc. is a biotechnology company that specializes in the development of gene and cell therapies. The company was formerly known as Intrexon Corporation and was founded in 1998. Precigen operates through four main business segments: Health, Food, Energy, and Environment.
The Health segment of Precigen focuses on developing gene therapies for rare genetic diseases, cancer, and autoimmune disorders. The Food segment is focused on developing genetically modified organisms (GMOs) for agriculture and aquaculture. The Energy segment is focused on developing renewable energy sources, such as algae-based biofuels. The Environment segment is focused on developing solutions for environmental remediation and pollution control.
Precigen has partnerships with several major pharmaceutical companies, including AstraZeneca, Merck, and Ziopharm Oncology. The company has also received funding from the U.S. government, including a $25 million grant from the Defense Advanced Research Projects Agency (DARPA) to develop a new treatment for antibiotic-resistant bacteria.
In 2020, Precigen announced that it was spinning off its agriculture and food business into a separate company called Surterra Wellness. The move was aimed at allowing Precigen to focus more on its core gene and cell therapy business.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The Health segment of Precigen focuses on developing gene therapies for rare genetic diseases, cancer, and autoimmune disorders. The Food segment is focused on developing genetically modified organisms (GMOs) for agriculture and aquaculture. The Energy segment is focused on developing renewable energy sources, such as algae-based biofuels. The Environment segment is focused on developing solutions for environmental remediation and pollution control.
Precigen has partnerships with several major pharmaceutical companies, including AstraZeneca, Merck, and Ziopharm Oncology. The company has also received funding from the U.S. government, including a $25 million grant from the Defense Advanced Research Projects Agency (DARPA) to develop a new treatment for antibiotic-resistant bacteria.
In 2020, Precigen announced that it was spinning off its agriculture and food business into a separate company called Surterra Wellness. The move was aimed at allowing Precigen to focus more on its core gene and cell therapy business.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!